• Shinsuke Sasada, Makoto Kodaira, Tatsunori Shimoi, Akihiko Shimomura, Mayu Yunokawa, Kan Yonemori, Chikako Shimizu, Yasuhiro Fujiwara, and Kenji Tamura.
• Department of Breast and Medical Oncology, National Cancer Center Hospital, Tokyo, Japan.
• Anticancer Res. 2016 May 1; 36 (5): 2429-32.

BackgroundNo standard chemotherapy for adults with recurrent/refractory rhabdomyosarcoma (RMS) has yet been established. The present study aimed to assess the effect of ifosfamide and etoposide (IE) chemotherapy on previously treated RMS.Patients And MethodsAdults with recurrent/refractory RMS were treated with ifosfamide (1,800 g/m(2)/day), etoposide (100 mg/m(2)/day) and mesna (1,080 mg/m(2)/day) for 5 days. The effect and toxicity were evaluated by chart review.ResultsFifteen patients, with a median age of 33 years (range=25-67 years), were treated with IE chemotherapy. A median of six cycles of chemotherapy were administered and an objective response was obtained in eight patients. The median progression-free survival was 5.2 months (95% confidence interval=2.3-6.7 months) and overall survival was 14.4 months (95% confidence interval=4.6-28.3 months). Toxicity greater than grade 3 was as follows: neutropenia in all patients, anemia in seven, thrombocytopenia in seven and febrile neutropenia in eight.ConclusionIE chemotherapy could be an alternative optional treatment method in adults with recurrent/refractory RMS.Copyright© 2016 International Institute of Anticancer Research (Dr. John G. Delinassios), All rights reserved.

18 keywords...

hide…